BASEL, Switzerland, May 9, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF):
Incontinence treatment Enablex(R) purchased from Pfizer for up to USD 225 million
51% of Idenix acquired, marking strategic expansion into antiviral medicines
Having obtained regulatory authorizations, Novartis has completed two significant strategic acquisitions, complementing the company's robust pipeline with a number of promising therapies with potentially significant benefits for patients around the world. The deals were both announced in March.
Please find press release as pdf under the following link http://reports.huginonline.com/902926/117589.pdf